The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Phase III STArT trial results: sickle cell disease treatment with arginine therapy
Claudia Morris, MD, Emory University School of Medicine, Atlanta, GA, discusses results from the Phase III STArT trial (NCT04839354) evaluating intravenous arginine for acute pain management in children and young adults with sickle cell disease (SCD). Although the study did not meet its primary endpoint of time-to-crisis-resolution (TCR), Dr Morris highlights important insights into the limitations of current pain endpoints and signals of benefit in specific subgroups. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
